The results of studies with cultured endothelial cells have shown that most von Willebrand factor (vWF) synthesized is directly secreted (constitutive pathway) and consists of both mature vWF, its precursor molecule pro-vWF, and the cleaved vWF prosequence. Only fully processed, functionally mature vWF is stored within the cell, together with the propeptide, and leaves the cell only on stimulation (regulated secretion). Both in resting and stimulated cultured endothelial cells, the stoichiometry of the released propeptide t o the released mature vWF is essentially equimolar. In the present study, we have memured the molar ratio of propeptide t o mature vWF in vivo, both under resting conditions and conditions that reflect activation of the endothelium. To this end, we devised a method that allows the measurement of the propeptide (vW antigen II) on a quantitative, ie, molar basis, using purified recombinant propeptide as a standard. Our results show that the molar concentration of the pro-ON WILLEBRAND FACTOR (vWF) is a large adhesive glycoprotein that mediates the adhesion of platelets at sites of vascular injury and functions as a stabilizing carrier protein of coagulation Factor VIII.'.' vWF is synthesized by vascular endothelial cells and megakaryocytes. Before de novo synthesized vWF leaves the endothelial cell, it undergoes a number of posttranslational modifications, including dimerization, glycosylation, polymerization of homodimers, endoproteolytic cleavage of the propeptide (also known as VW antigen and sulfation: Most of the vWF synthesized is secreted through the constitutive pathway. The remainder is stored in specialized secretory vesicles, the Weibel-Palade bodies, and leaves the cell only on stimulation.'-* Part of vWF released constitutively is proteolytically incompletely processed and, because of its limited degree of polymerization, is functionally less ~ompetent.'.'~ In contrast, vWF released through the regulated pathway is proteolytically fully processed, and consists of biologically potent, high molecular weight multimers.
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Both in resting and in stimulated cultured endothelial cells, the stoichiometry of the released propeptide to the released mature vWF is essentially equimolar." It is of interest to know also whether in vivo these polypeptides are released into the circulation in equimolar amounts and whether the plasma concentration of these molecules differs. As it is likely that the half-lives of mature vWF and its propeptide differ, activation of the endothelium in vivo would result in changes of the molar ratio of propeptide to mature vWF. Therefore, measurement of this parameter could be of help in assessing the extent of pertubation of the vascular endothelium on a quantitative basis. This hypothesis led us to examine the actual, ie, molar, concentration of the propeptide and mature vWF in both cultured endothelial cells and healthy subjects who received either endotoxin or l-deamino-8-Darginine vasopressin (DDAVP). These conditions were chosen to induce an intravascular increase of vWF and of its propeptide.
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MATERIALS AND METHODS

Materials
Culture media and antibiotics were purchased from GIBCO (Paisley, UK). 4p-Phorbol 12-myristate 13-acetate (PMA) and transferrin were from Sigma (St Louis, MO). Glutamine was purchased from Merck (Darmstadt, Germany). [35S]rnethionine was obtained from Amersham (Amersham, UK). Polyclonal antibodies to vWF were from Dakopatts (Glostrup, Denmark). Protein-A Sepharose and gelatin-Sepharose were obtained from Pharmacia LKEZ (Uppsala, Sweden). Culture plates were purchased from Costar (Cambridge, MA). Human serum albumin was from our institute. All reagents were of the best grade available.
Transfection and Cell Culture
Murine AtT-20 cells expressing a mutant vWF cDNA that encodes an uncleavable pro-vWf molecule (pro-vWFgly763) were obtained as follows. Plasmid pRC/RSVvWFgly763 was prepared by inserting an 8.8-kb EcoRI-EcoRI fragment isolated from ~SVLvWFgly763'~ into pRC/RSV (InVitrogen, Leek, The Netherlands). The resulting plasmid was transfected into murine AtT-20 cells as described previously." AtT-20 cells expressing either wild-type or mutant vWF that lacks propolypeptide (vWFdelpro) have been described elsewhere.I3 Transfected cells were cultured in Iscove's medium containing 10% (vol/vol) fetal calf serum, penicillin (100 U/mL), and streptomycin (100 pg/mL). On confluency, cells were washed twice with phosphate-buffered saline and incubated for 24 hours in serumfree medium. Conditioned medium was harvested and centrifuged at 600g for 5 minutes to remove cell debris, and benzamidine was added to a final concentration of 10 mmol/L. Conditioned media were stored at -30°C until use.
Endothelial cells were isolated from human umbilical cord veins as previously de~cribed,'~ with some modifications," and were grown in 80-cm2 fibronectin-precoated plastic flasks. The culture medium consisted of 40% (vol/vol) medium 199, 40% (vol/vol) RPMI 1640, and 20% (vol/vol) heat-inactivated pooled human serum with the addition of 2 mmol/L glutamine, penicillin (100 U/mL), streptomycin (100 pg/mL), and amphotericin (5 pglmL; GIBCO). Cells were passaged one time from primary cultures. Confluent cell monolayers were harvested by trypsinization and subcultured in 6-well culture plates.
Treatment of Endothelial Cells With PMA
Cells were washed 3 times with a mixture of 50% RPMI 1640 and 50% medium 199 and were treated with PMA (50 ng/mL) in serum-free medium consisting of an equal mixture of RPMI 1640 and medium 199, 0.5% human serum albumin, 20 pg/mL human transferrin, 2 mmoVL glutamine, penicillin (100 U/mL), and streptomycin (100 pg/mL). At the indicated time points, the medium was collected and kept at -30°C before analysis of mature vWF, propeptide, and pro-vWF by enzyme-linked immunosorbent assay (ELISA: see below).
Metabolic Labeling and Immunoprecipitation of Prov WF-Related Proteins
Metabolic labeling of cells was performed as described previously." Cells were starved for 30 minutes in RPMI medium lacking methionine, maintained for 4 hours in the same medium containing 10% (voUvol) heat-inactivated fetal calf serum dialyzed against HEPES buffer, supplemented with 
MoAbs
BALBk mice were immunized with 0.2 mL of purified vWFgly763 (see below; 3 pg/mL). Spleen cells from the hyperimmunized mice were fused to SP2/0 cells, and cell supernatants from the resulting clones were examined by differential screening as follows. Polyclonal anti-vWF IgG coupled to microtiter wells was first incubated with either vWFgly763-or vWFdelpro-containing medium of AtT-20 cells and subsequently with hybridoma supernatants. Binding of MoAbs to each mutant was monitored with peroxidaselabeled antimouse IgG. Cell supernatants that showed a positive reaction with vWFgly763 but not with vWFdelpro were further examined for propeptide specificity. Three cell lines were Identified (designated CLB-Pro 35, CLB-Pro 14.3, and CLB-Pro 17, respectively) that produced antibodies that exclusively reacted with media from AtT-20 cells expressing vWFgly763 but not with media from AtT-20 cells expressing vWFde1pro. MoAbs were purified from CUIture medium using Protein-A Sepharose chromatography according to the instructions of the manufacturer. The specificity of CLB-Pro 14.3 and CLB-Pro 35 (the antibodies that were used in the present study) was further established by immunoprecipitation and immunoblotting.
Purt3cation of the Propeptide and vWFgly763
Conditioned medium from AtT-20 cells expressing vWF (wildtype) was dialyzed at 4°C against Tris-NaCI buffer (0.1 mol/L NaCI, 50 mmol/L Tris, and 10 mmoVL benzamidine-HCI [pH, 7.41) and was applied to a column containing an MoAb (CLB-Rag 201) directed against mature vWF" coupled to CNBr Sepharose 4B (10 mglg Sepharose) to remove pro-vWF (and mature vWF). Subsequently, the effluent was applied to a CLB-Pro 35 column equilibrated with Tris-NaCI buffer, washed and eluted with Tris-NaCI containing 3 mol/L potassium thiocyanate (KCNS). Fractions were analyzed for propeptide, pro-vWF and mature vWF by ELISA (see below) and protein. Fractions were also examined by SDS-PAGE and immunoblotting vWFgly763 was purified by a similar procedure using Sepharose-CLB-Rag 35 as affinity matrix. The protein eluted with 3 mol& KCNS was used for the immunization of mice.
Determination of the Propeptide, Pro-vWF, and Mature v W F
Mature vWF was measured by ELISA essentially as described previously." Four murine antibodies directed against mature vWF (respectively, CLB-Rag 20, CLB-Rag 35, CLB-Rag 42, and CLBRag 56)19 served as solid-phase antibodies, and a polyclonal peroxidase-labeled anti-vWF IgG (DAKO NS, Glostrup, Denmark) was used as indicator antibody. Normal human plasma from a pool of 30 donors, assumed to contain 50 nmol/L of vWF (in half-homodimer),?" served as a standard.
Also for the measurement of pro-vWF, microtiter wells were coated with the MoAbs directed against mature vWF. Bound provWF was detected with the monoclonal antipropeptide antibody CLB-Pro 14.3 coupled to peroxidase. Conditioned medium from AtT-20 cells expressing vWFgly763 served as standard. The concentration of pro-vWF in this medium was assessed with the ELISA of mature vWF, using pooled normal plasma as standard.
To measure the propeptide concentration, microtiter wells were coated with CLB-Pro 35 and incubated with the sample. Subsequently, wells were washed, and the bound propeptide-containing protein was detected with CLB-Pro 14.3 coupled to peroxidase. Measurements were performed in duplicate with samples diluted to two different concentrations. Purified recombinant propeptide was used as standard.
Clinical Laboratory Studies
Endoroxin srudy group. Three healthy male subjects were studied. The studies were approved by the research and ethical committees of the Academic Medical Center, and written informed consent was obtained from the participants. Medical history, physical examination, and routine laboratory examination showed no abnormalities in all volunteers. The study subjects were nonsmokers and did not use any medication, and their electrocardiograms (ECG) and chest x-rays were within normal ranges. They were excluded from participation in the study if they had undergone any febrile disease within 2 weeks preceding the study.
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Design of endotoxin study. The study was designed as part of a study in which healthy male volunteers were treated with endotoxin, Escherichia coli 0113, K-, lot EC-5 (D. Hochstein, Bureau of Biologics, Food and Drug Administration, Bethesda, MD), administered as a 4-ngkg injection intravenously in 1 minute. The volunteers were confined throughout the study period at a clinical research unit. During the study period, they were under the continuous supervision of at least two physicians. Complete emergency and resuscitation equipment was immediately available. Vital signs such as heart rate, blood pressure, and oxygen saturation were monitored every 30 minutes using a Dinamap device (Criticon, Tampa, FL) during the first 6 hours after endotoxin administration. Temperature and respiratory rate were assessed at the same time points.
Sampling and assays. At the time points indicated, blood for the measurement of the propeptide and mature vWF was collected by separate venous punctures from antecubical veins. Blood was collected in vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ) containing 3.2% buffered citrate solution (anticoagulant-to-blood ratio, 1:9 vol/vol) and was immediately placed on ice. After centrifugation at 3,000g for 20 minutes at 4"C, plasma was aliquoted and stored at -70°C until batchwise assessment.
DDAVP study. This study group consisted of four males and one female. They were all healthy and free of medication. One male subject is a smoker. Each individual received intravenous infusion of DDAVP (0.4 pgkg body weight) in 100 mL of saline over a 30-minute period as described." Blood samples were collected and processed as described above.
To assess the normal concentration of mature vWF and of its propeptide, blood was obtained from 47 healthy subjects (25 men and 22 women, aged 21 to 70 years).
Miscellaneous. SDS-PAGE and immunoblotting were performed as described.2z The protein concentration was determined by the Bradford method.23 IgG of antibody CLB-Pro 14.3 was coupled to peroxidase as
RESULTS
MoAbs to the Propeptide
Immunization of a mouse with purified vWFgly763 and subsequent subcloning and differential screening of the hybridomas resulted in the identification of three MoAbs that reacted only with pro-vWF and wild-type vWF produced by AtT-20 cells and not with vWFdelpro. The specificity of two of these antibodies, designated CLB-Pro 14.3 and CLB-Pro 35, was further established by immunoprecipitation. Both CLB-Pro 35 and CLB-Pro 14.3 recognize three molecular species most likely identical to pro-vWF, mature vWF, and the propeptide (Fig 1) . An MoAb against mature vWF (CLBRag 201)'' recognized two metabolically labeled proteins, representing mature and pro-vWF, respectively. vWFdelpro was readily identified with CLB-Rag 201 but was not recognized by CLB-Pro 14.3 and CLB-Pro 35. None of the antibodies examined reacted with untransfected AtT-20 cells. On the basis of these observations, it seems justifiable to conclude that both CLB-Pro 14.3 and CLB-Pro 35 are directed against the propeptide, either in its uncleaved configuration (pro-vWF) or in its free form. Similar findings were obtained with media from endothelial cells (data not shown). The observation that the antipropeptide antibodies also recognize mature vWF is likely caused by the coprecipitation of partially and completely processed vWF species that are covalently linked. Figure 2 shows the SDS-PAGE pattern of the propeptide purified by CLB-Pro 35-affinity chromatography from the conditioned medium of AtT-20 cells. Apparently, homogeneous propeptide can be obtained by this 2-step procedure. The mobility of the propeptide in its reduced form is lower than that of the unreduced propeptide, suggesting a tight disulfide-linked conformation of the unreduced molec~le.~ Both CLB-Pro 14.3 and CLB-Pro 35 recognized the purified protein by Western blot analysis, although only propeptide in unreduced form (data not shown). The purified protein was used as standard for the measurement of propeptide concentrations in different culture media and plasma samples.
PuriJication of the Propeptide
Measurement of the Propeptide, Mature vWF, and ProvWF Figure 3 shows the dose-response curves of ELISAs of the propeptide, pro-vWF, and mature vWF, respectively, either secreted by AtT-20 cells or present in pooled normal plasma. The specificity of the propeptide ELISA is reflected by the observation that, with this assay (using the antibody combination CLB-Pro 35konjugated CLB-Pro 14.3), no antibodybinding protein was detectable in the medium of AtT-20 cells producing vWFdelpro (Fig 3, middle panel) . On the other hand, propeptide-related protein was detectable in conditioned medium of cells that produce a pro-vWF mutant that lacks the propeptide cleavage site (vWFgly763). Apparently, endoproteolytic cleavage of the propeptide is not a prerequisite for recognition of the propeptide region by the antibodies CLB-Pro 35 and CLB-Pro 14.3.
With the pro-vWF ELISA only in the medium of AtT-20 cells that produce wild-type vWF or vWFgly763, pro-vWF protein was detectable; however, it was not detectable in normal plasma (mixture of 30 donations; detection limit, 30 pmoVL) or in the medium of AtT-20 cells that produce vWFdelpro (Fig 3, right panel) . In the majority of the individual plasma samples examined, no or very little pro-vWF was detectable (see below). It should be noted that mature vWF competes for the binding of pro-vWF to the antibodies coated to the microtiter wells. When recombinant pro-vWF was added to plasma that was virtually devoid of endogenous pro-vWF, the amount of pro-vWF bound was dependent on the vWF concentration of the plasma sample (data not shown). Because the vWF concentration may vary considerably under various (patho)physiological conditions, this variance would affect the precision of the measurements of provWF concentrations. No further attempts were made to develop a pro-vWF assay that is independent of fluctuations of mature vWF.
The analysis of the various samples, including culture media and plasma, showed parallel dose-response curves. This parallelism allows comparison and calculation of the antibody-binding response on a quantitative basis. Similarly, parallel dose-response curves were obtained with the propeptide ELISA of respectively purified propeptide and normal plasma (not shown). On the basis of this observation, we calculated, using purified propeptide as a standard (46 pgI (see also below). The coefficients of variation of the ELISA of mature vWF and propeptide were 10.7% and 3.3%, respectively.
Release of the Propeptide, Mature vWF, and Pro-vWF by Endothelial Cells
Quantitative analysis of the release of the propeptide, mature vWF, and pro-vWF by endothelial cells showed that these proteins were secreted by the constitutive pathway at a constant, steady rate (Fig 4) . PMA-induced stimulation of endothelial cells resulted in enhanced and rapid secretion of both mature vWF and its propeptide in nearly equimolar amounts. This observation supports the view that these polypeptides stem from an intracellular storage pool that contains vWF predominantly in its processed form?*' This view is underscored by the observation that exposure of endothelial cells to PMA did not result in a substantial enhanced release of pro-vWF (Fig 4) . Figure 5 shows the individual molar concentration of the propeptide and mature vWF in 47 healthy subjects. The correlation between propeptide and vWF concentrations was poor ( r = .25), with mean concentrations ( 2 2 SD) of 5.5 2 2.3 and 49.0 2 26.8 nmol/L, respectively, indicating a molar ratio of about 0.1. This ratio is clearly different from the molar ratios established in the conditioned medium of endothelial cells (Fig 4) . The mean of the individual molar ratios was 0.13 (range, 0.04 to 0.23). In 4 of 47 individuals tested, some pro-vWF was also detectable (less than 0.1 nmol/L).
Propeptide, Mature vWF, and Pro-vWF in Normal Plasma
DDAVP-and Endotoxin-Induced Release of Propeptide, Mature vWF, and Pro-vWF
In all of the subjects studied (n = 5), infusion of DDAVP led to a prompt increase in both mature vWF and the propep- ized disappearance curves (Fig 6, inset) , were about 2 and 12 hours, respectively. In none of the 5 subjects examined was pro-vWF detectable before administration of DDAVP. However, in 2 of these subjects, some pro-vWF was detectable (about 50 pmoVL) after injection of DDAVP (data not shown).
Also, on injection of E coli endotoxin, another agonist known to elicit vWF release in vivo, the concentration of both mature vWF and the propeptide markedly increased, although with a delay of about 1 hour (Fig 7) . The maximal concentrations of these proteins (about 3 hours after endotoxin injection) were similar to the plasma levels after DDAVP stimulation. Also, the results of this study showed that the propeptide disappeared from the circulation at a higher rate than that of mature vWF. Endotoxin induced an increase of the pro-vWF concentration similar to that of DDAVP in all of the subjects examined. Also, under this condition, the concentration of pro-vWF, compared with that of either the propeptide or mature vWF, was relatively low after stimulation (about 20 pmol/L).
DISCUSSION
This study on the measurement of the molar concentrations of mature vWF and the free propeptide in healthy subjects showed some interesting features. First, the vWFpropeptide is a rather abundant protein (5 to 100 nmol/L, depending on the state of activation of the endothelium). This observation is compatible with the view that, in addition to its function as a mediator of intracellular polymerization, the propeptide also may serve additional biological functions extracellularly.2"29 Second, the molar ratio of the propeptide and mature vWF in the circulation ranges from about 0.1 under apparent resting conditions (Fig 5 ) to about 0.4 after endotoxin-or DDAVP-induced stimulation (Figs 6 and 7) . These values are clearly lower than the molar ratio observed in cultured endothelial cells (Fig 4) .".30
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The validity of this approach is underscored by the observation that, under both resting conditions and on stimulation with PMA, endothelial cells release the propeptide and mature vWF in apparently equimolar amounts (Fig 4) , a feature that has been noticed previously using immunoprecipitation techniques.'." Similarly, stably transfected AtT-20 cells release the free propeptide and mature vWF in about equimolar quantities (not shown). Therefore, it seems justifiable to conclude that this approach is appropriate to assess the in vivo propeptide concentration on a molar basis. In previous studies on the measurement of in vivo propeptide levels, concentrations were expressed in relative terms (eg, units per deciliter) and did not allow conclusions as to the absolute concentration of the pr~peptide?'.~~
The observation that the concentration of circulating propeptide is significant raises a number of questions. For instance, where does the propeptide originate? Or, what is the biological significance of the persisting propeptide level? As to the first point, it seems likely that, under both resting conditions and after administration of either DDAVP or endotoxin, the propeptide (and mature vWF) originates from the endothelium. In preliminary studies, we observed that the amount of propeptide stored in platelets (approximately 5 pmol propeptide/lO' platelets) is probably not sufficient to account for the massive amounts found in the plasma after stimulation (10 to 20 times the baseline concentration). Therefore, it seems likely that, under the experimental conditions examined, the propeptide, together with mature vWF, is released from the endothelium. This view is supported by recent observations that show that injection of DDAVP elicits responses that are clearly related to activation of endothelial cells, such as expression of P-selectin and subsequent margination of leukocyte^,^^ and does not lead to significant platelet activati01-1.~~
In cuItured endothelial cells, mature vWF and its propeptide share the same intracellular pathways, including the constitutive and regulated pathways, and are secreted at the same rate. Because the propeptide seems to disappear 3 to 4 times faster from the circulation than does mature vWF (Figs 6  and 7) , it is not unexpected, therefore, that the steady state concentrations of these molecules differ several fold, at least under resting conditions (Fig 4) . This molar ratio clearly changes on perturbation of the endothelium. For instance, on injection of DDAVP, the molar ratio of propeptide to mature vWF may promptly increase up to fivefold, a phenomenon that can readily be explained in terms of acute release of equimolar amounts of these polypeptides through the regulated pathway. Similarly, injection of endotoxin leads to a clear increase in this ratio. These observations suggest that measurement of the molar ratio of these proteins provides a means to assess the extent of activation of the endothelium under physiological and pathophysiological conditions. Studies are underway to test this hypothesis.
As to the biological significance of the persisting and significant amounts of propeptide in the circulation, it has been suggested that the propeptide, in addition to its intracellular function, serves a number of other biological functions. For instance, the propeptide may bind to extracellular matrix proteins such as collagens and laminin or (mature) vWF by Factor XIII.26.27 As such, the propeptide could serve a role in controlling platelet-vessel wall interaction. It has also been proposed that the propeptide possesses cytokine-like and tissue factor-inducing a~tivity.~',*~ The results of further studies should show whether indeed endoproteolytic cleavage of pro-vWF results in two polypeptide species with distinct biological functions, a process that is reminiscent of the physiology of prohormone processing.36337 itself,25.26.35 a process that, at least in part, could be catalyzed
